Antihypertensive Drugs Market Research Report - Global Forecast to 2027

Antihypertensive Drugs Market Research Report: By Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others) - Forecast till 2027

ID: MRFR/Pharma/1731-CR | January 2019 | Region: Global | 124 pages

Antihypertensive Drugs Market Overview

The Antihypertensive Drugs Market size can touch USD 41,123.2 Million by 2023, according to the extensive research conducted by Market Research Future (MRFR). MRFR identifies the rising number of awareness campaigns by governmental and non-profit organizations across the world as one of the reasons for market growth.

COVID-19 Analysis

Antihypertensive drugs market share has declined owing to the lockdown imposed following the COVID-19 outbreak. The novel coronavirus pandemic has reduced the number of cardiac surgeries in view of the re-scheduling, no-show by patients, cancellations and lower consultations in the wake of restrictions by health authorities and government. In view of the steadily growing number of SARS-CoV-2 cases, only emergency services are currently being allowed, while the decrease in heart disease hospital admissions has slowed down the market growth.

However, MRFR experts believe that the market could be resilient over the forthcoming period. This can be the case since latest studies show that COVID-19 patients are dealing with sevaerl cardiovascular complications, and as a result, health authorities are encouraging the use of CVD drugs and antihypertensive drugs. This could ensure sustainable market growth in the years to follow. Surging popularity of e-commerce and online drug stores will also result in antihypertensive drugs market expansion during the review period, despite the escalating novel coronavirus cases.

Antihypertensive Drugs Market Dynamics

Drivers

Escalating Hypertension Cases Worldwide to Push Market Growth

One of the foremost growth rendering factors in the antihypertensive drugs market is the alarming rise in incidences of hypertension across countries. The growing cases are also raising the awareness level among the mass about the complications related to hypertension, which also encourages market growth. The consistently expanding geriatric pool across the globe along with the high prevalence of sedentary lifestyle fosters major growth as well. The mounting need for early diagnosis as well as treatment of hypertension is bolstering the demand for antihypertensive drugs in the market. Some of the modern anti-hypertensive drugs in the market that are used for treatment include ACE inhibitors, vasodilators and diuretics. However, these antihypertensive drugs in pregnancy are advised to be avoided so as not to give way to any complications.

Opportunities

Rising Preference for Combination Therapy to Offer Opportunities

Of late, combination therapies have witnessed significant applications compared to the monotherapy form of treatment. Monotherapy involves the use of a single drug, whereas combination therapy facilitates action on multiple hypertensive mechanisms. The latter involves combining two drugs that have varying mechanisms of action, which leads to an effect that is much higher than monotherapy.

Combination therapy helps bring down cerebrovascular events by 54% and coronary issues by 40%. Therefore, combination therapy offers better protection to the organ with lower dose compared to monotherapy and its wide acceptance across the world is proving to be a lucrative opportunity for leading firms in the global industry.

Restraints

Lower Awareness Levels in Developing Countries to be a Key Restraint

Lower awareness levels with regard to antihypertensive drugs amongst the mass in developing countries can be a huge restraint in the worldwide market. A vast population in developing countries tends to neglect health-checkups and has low knowledge about hypertension conditions and symptoms, which is making it hard for players to gain any profits in these regions.

Challenges

Patients with hypertension generally do not adhere to the required medication schedule and tend to stop medications in only 1 to 2 weeks, which gives rise to the symptoms again. This passive attitude of patients is posing a significant challenge to the firms in the anti-hypertensive drugs industry. For instance, in 2016, BMC Research conducted a research that stated that only 17% of 112 hypertensive individuals with stroke adhered to antihypertensive drugs and medications.

Cumulative Growth Analysis

Introduction of New Treatment Options to Bolster Market’s Growth Rate

The antihypertensive drugs market growth is expected to be at a rate of 2.67% over the analysis period (between 2015 and 2023), on account of the rising introduction of new antihypertensive therapy options.

Antihypertensive Drugs Market Segment Overview

Cost Effectiveness to Bolster Demand for Beta Blockers

MRFR’s review of anti-hypertensive drugs market outlines a few key therapeutic classes, namely beta-adrenergic blockers, calcium channel blockers, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, renin inhibitors, diuretics, vasodilators, and others. Latest studies have concluded that antihypertensive drugs beta blockers and diuretics are far more cost-effective compared to other therapeutic classes and therefore, observe considerable demand in the antihypertensive drugs market.

Secondary Hypertension-Based Drugs to observe Strong demand

Depending on the type of anti-hypertensive drugs in the antihypertensive drugs market are primary as well as secondary. Secondary hypertension segment is in the lead owing to early diagnosis, faster detection, surging cases of thyroid problems, chronic alcohol use, kidney problems, heart ailments, adrenal gland tumors and more. However, the antihypertensive drugs classification by MRFR also reveals that the segmental growth can be slowed down by patent expiries including United Therapeutic's Remodulin (2014) and Actelion's Tracleer (2015).

E-Commerce Websites and Online Drug Stores Gain Massive Popularity

Distribution channels highlighted in the MRFR study are retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. E-commerce websites and online drug stores segment can expect to surge forward at the fastest rate over the evaluation period, on account of the high internet usage and popularity of smartphones and tablets.

Antihypertensive Drugs Market Regional Analysis

America to Reach the Leading Position in the Coming Years

AHA or American heart association claims that close to 74.9% of the total hypertension patients in North America are being treated while only about 52.2% of them have it under control. AHA also projects that by the year 2030; roughly 41.4% of individuals in the US/United States will suffer from hypertension. These scaling numbers indicate the bright growth prospects of the American market for antihypertensive drugs. Also, the mounting need for accurate and prompt diagnosis as well as treatment of hypertension, detecting people that are predisposed to the disorder and the presence of modern healthcare infrastructure also work in favor of the American anti-hypertension industry. The orthostatic hypotension drugs market has been growing exponentially in the region, with a soaring number of patients suffering from low blood pressure.

APAC Races Ahead at the Fastest Rate as China and India Take the Lead

MRFR anticipates the APAC antihypertensive drugs market to exhibit the fastest growth during the conjectured period, thanks to the soaring awareness level about antihypertensive drugs and other treatment options. The stunning growth of the life science industry in India, Malaysia and China has also been an important growth booster in the APAC market. The anti-hypertensive drugs rhabdomyolysis are gaining traction in the region, in view of the surge in alcohol abuse, rising intake of toxic substances and overexertion. The rising availability of various categories of anti-hypertensive drugs in the region and growing access to these also promote market expansion. The growth of the antihypertensive drugs market in India can be directly linked to the rising consumption of unhealthy or junk food, lack of balanced and healthy diet, improper sleep owing to irregular working hours that result in hypertension. These factors have amplified the rate of diseases like stroke, heart failure, chronic kidney disease, peripheral vascular disease and more.

Antihypertensive Drugs Market Competitive Landscape

Significant Investments by Players to Intensify Competition

Anti-hypertensive drugs market is quite stable, since it is rife with several affluent firms. The expected market growth rate is sluggish owing to the rising use of generic drugs. Substantial spending by leading manufacturers in developing new drugs and medicines is a major trend that can continue throughout the review period. Prominent growth strategies that are primarily employed by the top vendors in the market include agreement, product launch, acquisition, expansion and partnership.

Merck is an eminent antihypertensive drug brand that aims to produce medicines as well as vaccines for highly challenging disorders. The company is known for its commitment to the global population’s health by enabling patients to have access to advanced healthcare via far-reaching programs, policies, and partnerships. Merck has also always been at the forefront of extensive researches for preventing and treatment of various diseases, which also include hypertensive disorders.

List of Key Companies Covered in this Report

Sanofi S.A.

Takeda Pharmaceuticals Company Limited

Boehringer Ingelheim

Novartis AG

Pfizer Inc.

Ranbaxy Laboratories Limited Inc.

Daiichi Sankyo Company Limited

Astra Zeneca plc

Acetelion Ltd

Recent Developments

December 2020 – Quantum Genomics, a biotech firm with expertise in class of drugs that address difficult-to-treat hypertension and heart failure, signed a contract with Delpharm, for manufacturing of its upcoming clinical range of firibastat tablets.

June 2020 – JB Chemicals and Pharmaceuticals Ltd, a well-known vendor specializing in Calcium Channel Blockers ranges for hypertension management, has launched its latest CCB in India called Azelnidipine, under the brand name Azovas. The drug is expected to be quite useful for Diabetologists, Physicians and Cardiologists for managing hypertension.

Report Overview

Scope of the Report

The scope of the report highlights drivers, opportunities, restraints and challenges surrounding the global market. With easy-to-comprehend segmentation that includes antihypertensive drugs classification, therapeutic class, distribution channel, as well as region, MRFR projections are on the basis of historical as well as expected trends. Major firms active in the global market have been profiled as well, paired with the top strategies employed by them to remain competitive in the industry.

Segmentation Table

Therapeutic Class

Calcium Channel Blockers

Beta-adrenergic Blockers

Renin Inhibitors

ACE Inhibitors

Vasodilators

Diuretics

ARBs

Others

Type

Primary Hypertension

Secondary Hypertension

Distribution Channel

E-commerce Websites & Online Drug Stores

Retail Pharmacy

Hospital Pharmacy

Others

Report Scope:

Report Attribute/Metric	Details
Market Size	USD 41,123.2 Million
CAGR	2.67% (2018-2023)
Base Year	2019
Forecast Period	2020-2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Therapeutic Class, Type and Distribution Channel
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Sanofi S.A., Takeda Pharmaceuticals Company Limited, Boehringer Ingelheim, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited Inc., Daiichi Sankyo Company Limited, Astra Zeneca plc, Acetelion Ltd
Key Market Opportunities	Rising Preference for Combination Therapy to Offer Opportunities
Key Market Drivers	Escalating Hypertension Cases Worldwide to Push Market Growth

Frequently Asked Questions (FAQ) :

What valuation the Antihypertensive Drugs Market would achieve by 2023?

Antihypertensive Drugs Market can grow up to a valuation of USD 41,123.2 million by 2023.

With what growth rate the Antihypertensive Drugs Market is slated to grow during the forecast period of 2018 to 2023?

Antihypertensive Drugs Market would grow with a valuation of 2.67% CAGR during the forecast period of 2018 to 2023.

What are the distribution channels involved in the Antihypertensive Drugs Market?

Antihypertensive Drugs Market has distribution channels like retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others.

Which region has the lead in the global Antihypertensive Drugs Market?

Americas has a maximum Antihypertensive Drug Market growth.

What are the prime Antihypertensive Drugs Market driver?

Long-term high blood pressure is the primary antihypertensive drugs, market driver.

Antihypertensive Drugs Market - Summary

Overview:

Antihypertensive drugs are a class of chemicals capable of lowering high blood pressure or hypertension. Antihypertensive treatment recommended by clinicians and doctors include antihypertensive drugs which can reduce the probability of stroke and myocardial infarction. Different classes of these drugs include beta blockers, angiotensin receptor II antagonists (ARBs), ACE inhibitors, calcium channel blockers, and thiazide diuretics.

Increasing cases of hypertension is the primary driver of the antihypertensive drugs market. This is supported by data provided by the World Health Organization (WHO) which has witnessed the incidence of high blood pressure in the number of adults above the age of 22 to shoot up considerably. Awareness campaigns by government and non-government organizations can net the antihypertensive drugs market much-needed support.

High prevalence of chronic diseases is expected to spike up the production of antihypertensive drugs. According the Centers for Disease Control and Prevention (CDC), nearly 1 in 3 U.S. adults have high blood pressure. Launch of generic versions of patented drugs is likely to fuel the market growth. This is expected to lower the patient treatment costs of high blood pressure and augur well for the antihypertensive drugs market.

Segmentation:

Type-wise, the antihypertensive drugs market is segmented into primary and secondary hypertension. Primary hypertension accounted for a large share of the market in 2017 owing to genetic factors, insulin resistance, and sedentary lifestyle. Secondary hypertension accounted for a smaller market share in the same year. This percentage can fluctuate owing to consumption of cocaine, endocrine disorders, and vascular disorders.

By therapeutic class, the market is segmented into vasodilators, ACE inhibitors, renin inhibitors, diuretics, ARBs, beta-adrenergic blockers, calcium blockers, and others. Diuretics was the leading drug in the antihypertensive drugs market and indicated by maximum number of clinicians for treating hypertension. But ACE inhibitors are expected to grow exponentially owing to the ability of the drug to dilate blood vessels and lower the blood pressure. In addition, ARBs can contribute to market revenue owing to being recommended for hypertension treatment for adults above 55.

Distribution channels in the antihypertensive drugs market include hospital pharmacy, online pharmacy, e-commerce websites & online drug stores, and others. Retail pharmacy accounted for the lion’s share of the market in 2017. This can be due to setups of pharmacy outlets at ideal locations. But the segment can lose its position to e-commerce websites & online stores by 2023. This can be attributed to its customer-first model and adoption of digitization which cater to demands of patients.

Regional Analysis:

The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.

The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.

The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.

Competitive Analysis:

Prominent players to get profiled in the antihypertensive drugs market report are United Therapeutics Corporation (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Sanofi S.A. (France), Merck KGaA (Germany), and Bayer AG (Germany).

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 17

3.2 Scope of the Study 17

3.3 List of Assumptions 17

3.4 Market Structure 18

4 Research Methodology

4.1 Research Process 20

4.2 Primary Research 20

4.3 Secondary Research 21

4.4 Market Size Estimation 22

4.5 Forecast Model 22

5 Market Dynamics

5.1 Overview 24

5.2 Drivers 24

5.2.1 Rising prevalence of hypertension 24

5.2.2 Growing initiatives by private and government organizations 24

5.2.3 Rise in the prevalence rates of chronic diseases 25

5.2.4 Increasing penetration of generic versions of drugs 25

5.3 Restraints 25

5.3.1 Side-effects of treatment options 25

5.3.2 High cost of treatment 25

5.3.3 Loss of patents 25

5.3.4 Rise in non-pharmacological therapy 25

5.4 Opportunity 26

5.4.1 Emerging therapies in the treatment hypertension 26

6 Market Factor Analysis

6.1 Value chain analysis 28

6.1.1 R&D and Designing 28

6.1.2 Manufacturing 28

6.1.3 Distribution & Sales 28

6.1.4 Post Sales Review 28

6.2 Porter’s Five Forces Model 29

6.2.1 Bargaining Power of Suppliers 29

6.2.1 Bargaining Power of Buyers 30

6.2.2 Threat of New Entrants 30

6.2.3 Threat of Substitutes 30

6.2.4 Intense Rivalry 30

6.3 Investment Opportunities 30

6.4 Pricing Analysis 31

7 Antihypertensive Drugs Market, by Therapeutic Class

7.1 Overview 33

7.2 Diuretics 34

7.3 ACE Inhibitors 35

7.4 ARBs 36

7.5 Calcium Channel Blockers 37

7.6 Beta-Adrenergic Blockers 38

7.7 Renin Inhibitors 39

7.8 Vasodilators 39

7.9 Others 40

8 Antihypertensive Drugs Market, by Type

8.1 Overview 42

8.2 Primary Hypertension 43

8.3 Secondary Hypertension 44

9 Antihypertensive Drugs Market, by Distribution Channel

9.1 Overview 46

9.2 Retail Pharmacy 47

9.3 Hospital Pharmacy 47

9.4 E-commerce Websites & Online Drug Stores 48

9.5 Others 48

10 Global Antihypertensive Drugs Market, by Region

10.1 Overview 50

10.2 Americas 51

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type